Mainous M R, Lipsett P A, O'Brien M
Department of Surgery, Louisiana State University Medical Center, Shreveport, USA.
Arch Surg. 1997 Jan;132(1):76-81. doi: 10.1001/archsurg.1997.01430250078017.
To determine the incidence and mortality rate associated with nosocomial bacteremia caused by vancomycin-resistant Enterococcus in a surgical intensive care unit.
A retrospective study.
The surgical intensive care unit of a large university hospital tertiary referral center.
All patients in the surgical intensive care unit with a documented nosocomial bacteremia between January 1, 1992, and December 31, 1994.
None.
Mortality rate.
Of the 134 nosocomial bacteremic episodes, 30.6% involved enterococci; 24.4% of the enterococci were resistant to vancomycin. Patients with vancomycin-resistant enterococcal bacteremia had a significantly longer hospital stay (mean +/- SD, 28 +/- 18 vs 12 +/- 10 days; P = .005) and were more likely to have been treated with vancomycin (70% vs 10.3%; P = .001) than patients with vancomycin-sensitive enterococcal bacteremia. The mortality (41.0%) associated with enterococcal bacteremia was similar to the overall bacteremic mortality (41.7%). There was no difference in episode-specific mortality associated with vancomycin-resistant enterococci (40%) vs vancomycin-sensitive enterococci (38.7%). Of the 4 deaths associated with vancomycin-resistant enterococcal bacteremia, only 2 occurred within 14 days of the bacteremia, as did 8 of 12 deaths associated with vancomycin-sensitive enterococcal bacteremia (P = .64).
Enterococci were the most commonly isolated nosocomial blood-borne pathogens in the surgical intensive care unit. Nearly 25% of the enterococcal bacteremic episodes were resistant to vancomycin. Vancomycin-resistant Enterococcus is associated with a prolonged hospital stay and with vancomycin use. Nevertheless, vancomycin resistance itself does not increase the mortality rate associated with enterococcal bacteremia.
确定外科重症监护病房中耐万古霉素肠球菌所致医院获得性菌血症的发病率和死亡率。
一项回顾性研究。
一所大型大学医院三级转诊中心的外科重症监护病房。
1992年1月1日至1994年12月31日期间外科重症监护病房中所有有医院获得性菌血症记录的患者。
无。
死亡率。
在134次医院获得性菌血症发作中,30.6%涉及肠球菌;24.4%的肠球菌对万古霉素耐药。与万古霉素敏感肠球菌菌血症患者相比,耐万古霉素肠球菌菌血症患者的住院时间显著更长(平均±标准差,28±18天对12±10天;P = 0.005),且更有可能接受过万古霉素治疗(70%对10.3%;P = 0.001)。肠球菌菌血症相关的死亡率(41.0%)与总体菌血症死亡率(41.7%)相似。耐万古霉素肠球菌(40%)与万古霉素敏感肠球菌(38.7%)相关的特定发作死亡率无差异。在与耐万古霉素肠球菌菌血症相关的4例死亡中,只有2例发生在菌血症后14天内,与万古霉素敏感肠球菌菌血症相关的12例死亡中有8例也是如此(P = 0.64)。
肠球菌是外科重症监护病房中最常见的医院获得性血源性病原体。近25%的肠球菌菌血症发作对万古霉素耐药。耐万古霉素肠球菌与住院时间延长和万古霉素使用有关。然而,万古霉素耐药本身并不会增加肠球菌菌血症相关的死亡率。